751 related articles for article (PubMed ID: 14520144)
1. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of linezolid in children.
Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
[TBL] [Abstract][Full Text] [Related]
3. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
4. Linezolid for the treatment of complicated skin and skin structure infections in children.
Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143
[TBL] [Abstract][Full Text] [Related]
5. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children.
Wible K; Tregnaghi M; Bruss J; Fleishaker D; Naberhuis-Stehouwer S; Hilty M
Pediatr Infect Dis J; 2003 Apr; 22(4):315-23. PubMed ID: 12690270
[TBL] [Abstract][Full Text] [Related]
6. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
7. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
9. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Sharpe JN; Shively EH; Polk HC
Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
[TBL] [Abstract][Full Text] [Related]
11. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
[TBL] [Abstract][Full Text] [Related]
14. Hematologic effects of linezolid in young children.
Meissner HC; Townsend T; Wenman W; Kaplan SL; Morfin MR; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S186-92. PubMed ID: 14520145
[TBL] [Abstract][Full Text] [Related]
15. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
[TBL] [Abstract][Full Text] [Related]
16. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
18. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
19. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
20. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]